Biocause Pharma(SZ:000627) Zheng Quan Zhi Xing·2025-08-08 15:17Core Viewpoint - The company intends to voluntarily terminate its A-share listing on the Shenzhen Stock Exchange through a shareholder resolution, facing significant uncertainties that may impact its operations and shareholder interests [1][2][9]. Group 1: Termination of Listing - The company plans to withdraw its A-share stock from the Shenzhen Stock Exchange and subsequently apply for transfer to the National Equities Exchange and Quotations (NEEQ) for management in the delisting section [2][7]. - The termination of the listing requires approval from more than two-thirds of the voting rights held by shareholders present at the meeting [3][9]. - If the shareholder resolution to terminate the listing is not passed, the company will apply for resumption of trading on the Shenzhen Stock Exchange [2][6]. Group 2: Cash Option for Shareholders - The company will provide a cash option to dissenting shareholders and other shareholders, excluding certain major shareholders, allowing them to receive cash compensation for their shares [4][6]. - The cash option price is set at 1.60 yuan per share, and shareholders must meet specific conditions to exercise this option [5][6]. - The cash option will be available to shareholders who are registered on the equity registration date, which is set for September 2, 2025 [6][7]. Group 3: Future Plans and Stability - After the termination of the listing, the company aims to maintain operational stability and protect shareholder rights, with no current plans for major asset restructuring or re-listing [7][9]. - The company will select a qualified securities firm to assist in the transfer process to the NEEQ [7][9]. - The company has engaged financial and legal advisors to ensure compliance with relevant regulations and to safeguard shareholder interests [9].